May 1st 2024
FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.
LRA Launches Initiatives to Increase Diversity in Lupus Research
Albert Roy, president of the Lupus Research Alliance, discusses the efforts his team are making to combat the underrepresentation of minorities in clinical trials as well as the scientific research profession.
RAIL Score Provides Useful, Noninvasive Biomarker for Renal Disease Activity
May 7th 2023An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively
Vitamin D Levels Can Influence Risk of Miscarriage, Premature Delivery in Women with Lupus
May 6th 2023An analysis of more than 250 pregnancies among women with SLE from the Hopkins Lupus Cohort provides insight into risk of adverse pregnancy outcomes based on serum 25-hydroxy vitamin D levels using real-world data.
Renal Biopsy Data Supports Long-Term Voclosporin Use for Lupus Nephritis
May 5th 2023Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.
Increased Risk of Fetal and Maternal Morbidity in Systemic Lupus Erythematosus
Compared with those without SLE, those with SLE had a higher risk of fetal morbidity and mothers were almost 4 times as likely to require a blood transfusion or develop a cerebrovascular disorder.